ArticleLupus science & medicine2026
Diagnostic accuracy of the Arabic composite autonomic symptom score 31 (COMPASS-31) for detecting autonomic neuropathy in SLE: a cross-sectional validation study.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the diagnostic accuracy of the Arabic Composite Autonomic Symptom Score-31 (COMPASS-31) for detecting objectively confirmed autonomic neuropathy in patients with SLE.
methodsIn this cross-sectional diagnostic accuracy study, 45 patients with SLE, 23 patients with neurologically confirmed autonomic neuropathy (positive-control group), and 45 healthy controls completed the Arabic COMPASS-31 before undergoing cardiovascular autonomic reflex testing (CART) and sympathetic skin response (SSR). Objective autonomic neuropathy was defined as abnormal CART and/or absent SSR. Diagnostic accuracy analyses (receiver operating characteristic (ROC) curve analysis, optimal cut-off determination and multivariable logistic regression) were performed within the SLE cohort.
resultsObjective autonomic neuropathy was present in 28 of 45 patients with SLE (62%). Total COMPASS-31 score discriminated autonomic neuropathy status with an area under the ROC curve (AUC) of 0.81 (95% CI 0.68 to 0.94) at a cut-off of ≥5 (sensitivity 89% and specificity 59%), increasing to 0.89 (95% CI 0.79 to 0.98) when restricted to definite/severe autonomic neuropathy. The orthostatic intolerance (AUC 0.78, 95% CI 0.64 to 0.91) and pupillomotor (AUC 0.77, 95% CI 0.64 to 0.90) domains performed similarly to the total score (DeLong's test, both p>0.4), while the vasomotor, secretomotor, gastrointestinal and bladder domains performed significantly worse. The COMPASS-31 total score remained independently associated with autonomic neuropathy after adjustment for age, disease duration and disease activity (adjusted OR 1.29, 95% CI 1.06 to 1.57). Internal consistency of the Arabic COMPASS-31 was good (Cronbach's α=0.83, McDonald's ω=0.857).
conclusionThe Arabic COMPASS-31 demonstrates good discrimination for objectively confirmed autonomic neuropathy in SLE, with the orthostatic intolerance and pupillomotor domains contributing most of its discriminative value. It can be used as a screening tool to identify patients who warrant confirmatory autonomic testing. Disease-specific validation should precede recommending COMPASS-31 as an autonomic neuropathy screening tool in other rheumatic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.